Eleven Biotherapeutics (EBIO) announced that its exclusive licensing deal with Roche for IL-6 inhibitor EBI-031 has been completed. According to the terms of the agreement, EBIO is entitled to receive $30M in payments ($7.5M upfront and $22.5M from the FDA's OK of the IND), up to $240M in milestones and royalties on net sales.